Key result
Penehyclidine hydrochloride protects rat cardiomyocytes from ischemia-reperfusion injury via PDGF-B upregulation and PI3K/AKT activation.
Why the study?
The lack of effective treatments for myocardial ischemia-reperfusion injury severely restricts the treatment of ischemic heart disease.
Does penehyclidine hydrochloride pretreatment protect rat cardiomyocytes from simulated ischemia-reperfusion injury?
Does penehyclidine hydrochloride pretreatment protect rat cardiomyocytes from simulated ischemia-reperfusion injury?
Penehyclidine hydrochloride demonstrates protective effects against myocardial ischemia-reperfusion injury in vitro by upregulating PDGF-B and activating the PI3K pathway.
Should not yet alter practice; extends preclinical evidence in rat cardiomyocytes.
AIMS AND OBJECTIVE: The lack of effective treatments for myocardial ischemiareperfusion (MI-R) injury severely restricts the effectiveness of the treatment of ischemic heart disease. In the present research, we aimed to investigate the protective effect and molecular mechanism of penehyclidine hydrochloride (PHC) on MI-R cells. METHODS: Cell viability was quantified using CCK8. Cell apoptosis was analyzed using flow cytometry. Western blot and Elisa assays were used for the detection of target proteins. RESULTS: PHC pretreatment attenuated the inhibition of cell viability and decreased the percentage of apoptosis induced by simulated ischemia reperfusion (SIR). Platelet-derived growth factor B (PDGF-B) and its downstream AKT pathway were activated in PHC pretreated cells. After siRNAPDGF- B transfection, cell viability was inhibited and apoptosis was activated in PHC pretreated SIR cells, suggesting that PHC protected cells from SIR. PDGF-B knockdown also increased the levels of CK, LDH, IL-6 and TNF-α in PHC pretreated SIR cells. The effect of AKT inhibitor on H9C2 cells was consistent with that of PDGF-B knockdown. CONCLUSION: PHC pretreatment can protect cardiomyocytes from the decrease of cell activity and the increase of apoptosis caused by reperfusion through up-regulating PDGF-B to activate PI3K pathway. Our study indicates that PHC is a potential drug to protect cells from reperfusion injury and PDGF-B is a potential target for preventing MI-R injury.
No takes yet. Share an insight, caveat, or question.
Lü et al. (2022) studied Myocardial ischemia-reperfusion injury. Penehyclidine hydrochloride (PHC) vs. Simulated ischemia reperfusion (SIR) without PHC was evaluated on Cell viability and apoptosis. Penehyclidine hydrochloride pretreatment protected rat cardiomyocytes from simulated ischemia-reperfusion injury by up-regulating PDGF-B and activating the PI3K/AKT pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: